PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach-Reference-Cited by-同舟云学术

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Published:2011-10 Issue:10 Volume:100 Page:4111-4126
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Vuppugalla Ragini,Marathe Punit,He Handan,Jones Rhys D.O.,Yates James W.T.,Jones Hannah M.,Gibson Christopher R.,Chien Jenny Y.,Ring Barbara J.,Adkison Kimberly K.,Ku M. Sherry,Fischer Volker,Dutta Sandeep,Sinha Vikash K.,Björnsson Thorir,Lavé Thierry,Poulin Patrick

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference29 articles.

1. On the anticipation of the human dose in First in man trials from preclinical and prior clinical information in early drug development;Lowe;Xenobiotica,2007

2. Projection of exposure and efficacious dose prior to first in human studies: How successful have we been;Huang;Pharm Res,2008

3. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: Strategic considerations;Gabrielsson;Drug Discov Today,2009

4. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data;Obach;J Pharmacol Exp Ther,1997

5. Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu Corrected Intercept Method’ (FCIM);Mahmood;J Pharm Sci,2006

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-17

2. Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example;The AAPS Journal;2024-01-05

3. Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css–MRTpo method and chimeric mice with humanised livers;Xenobiotica;2023-09-02

4. Quantitative Prediction of OATP-Mediated Disposition and Biliary Clearance Using Human Liver Chimeric Mice;Journal of Pharmacology and Experimental Therapeutics;2023-05-04

5. A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models;CPT: Pharmacometrics & Systems Pharmacology;2023-01-31